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ABSTRACT 
Objectives A few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) 
have been described but their frequency and evolution to typical CIDP remain unclear. To 
determine the frequency and characteristics of the CIDP variants, their possible evolution to typical 
CIDP, and treatment response. 
Methods We applied a set of diagnostic criteria to 460 patients included in a database of Italian 
CIDP patients. Clinical characteristics and treatment response were reviewed for each patient. The 
Kaplan-Meier curve was used to estimate the progression rate from atypical to typical CIDP.  
Results At the time of inclusion 376 (82%) patients had a diagnosis of typical CIDP while 84 
(18%) had atypical CIDP, including 34 (7%) with distal acquired demyelinating symmetric 
neuropathy (DADS), 17 (4%) with purely motor, 17 (4%) with Lewis-Sumner syndrome (LSS), and 
16 (3.5%) with purely sensory CIDP. Based on retrospective review of the symptoms and signs 
present at onset and for at least one year, 180 (39%) patients had an initial diagnosis compatible 
with atypical CIDP that in 96 (53%) patients evolved to typical CIDP. Mean disease duration was 
longer in patients evolving to typical CIDP than in those not evolving (p=0.0016). Patients with 
DADS and LSS had a less frequent response to immunoglobulin than those with typical CIDP, 
while patients with purely motor and sensory CIDP had a similar treatment response. 
Conclusions The proportion of patients with atypical CIDP varies during the disease course. DADS 
and LSS have a less frequent response to intravenous immunoglobulin compared to typical CIDP, 
raising the possibility of a different underlying pathogenetic mechanism. 
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INTRODUCTION 
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic and disabling 
immune-mediated polyradiculoneuropathy.[1] Several clinical variants of CIDP have been reported 
widening the spectrum of this neuropathy. These variants have been defined by the Joint Task Force 
of the European Federation of Neurological Societies and the Peripheral Nerve Society 
(EFNS/PNS) as ‘atypical CIDP’, and include distal acquired demyelinating symmetric neuropathy 
(DADS), purely motor or sensory CIDP, Lewis-Sumner syndrome (LSS) and focal CIDP.[1] The 
diagnostic criteria for these forms are however not well defined possibly explaining their variable 
frequency ranging from 1 to 49% in different series[2,3] and the reported differences in their 
treatment response.[4-7] It is also unclear the frequency and time to their possible evolution to 
typical CIDP.[5,8] 
We established a set of diagnostic criteria for the CIDP variants derived from a revision of the 
literature and applied it to a large series of patients with CIDP included in a web-based database on 
Italian CIDP patients, to determine the frequency and characteristics of the CIDP variants, their 
possible evolution to typical CIDP, and their treatment response. 
 
PATIENTS AND METHODS 
Database and study population 
From January 2015 to April 2018 we included data from 500 patients with a diagnosis of CIDP or 
one of its variants followed by 22 Italian Centers with expertise in immune-mediated neuropathies. 
The diagnosis of CIDP was made by the treating neurologist and reviewed by the coordinating 
Centre (PED and ENO) and classified according to the EFNS/PNS diagnostic criteria.[1] The 
reasons for suspecting CIDP when nerve conduction studies were not diagnostic were also reported 
by the treating neurologist and included, beside a clinical history and presentation consistent with 
CIDP, abnormality of the supportive tests[1] (CSF analysis, ultrasound or magnetic resonance 
imaging –MRI- of the nerves and plexus, sensory conduction studies or somatosensory evoked 
potentials, nerve biopsy and response to previous therapy) and a relapsing course of the disease. All 
the data were included by the treating neurologist in a web-based electronic database expressly 
prepared by CINECA, Bologna, Italy. Informed consent was obtained from all participants at 
enrollment.  
Diagnosis of atypical CIDP 
We reviewed the literature on the diagnostic criteria used for atypical CIDP [4-29] (supplementary 
table 1), and defined a set of clinical diagnostic criteria for all the patients included in our study 
(table 1). Our criteria include mandatory and exclusion criteria for each atypical CIDP form while 
symptoms and signs not essential for the diagnosis (but that may be part of the clinical picture) were 
defined as ‘other possible symptoms and signs’. We also decided that a minimum of one-year 
duration of symptoms and signs specific to each atypical form was necessary to establish a 
diagnosis of atypical CIDP. This because even typical CIDP may initially present with purely 
sensory or motor symptoms evolving over few months to a typical sensorimotor form. We defined 
purely sensory CIDP as a non-length dependent sensory neuropathy, DADS as a length-dependent 
sensory or sensorimotor neuropathy. Since however some authors included length-dependent purely 
sensory neuropathy as sensory CIDP we also separately analyzed the data of patients with sensory 
or sensorimotor DADS. We defined LSS as a sensory or sensorimotor multifocal neuropathy or in 
the presence of a clearly distinct degree of impairment among contiguous nerves. We included 
under this form focal CIDP where symptoms were homogeneously restricted to the nerves of one 
limb or two limbs (ipsilateral upper and lower limb). For chronic immune sensory 
polyradiculopathy (CISP) we used the criteria proposed by Sinnreich M. and coworkers.[9] 
Depending on the distribution of symptoms, patients with only sensory impairment were therefore 
split in our study into pure sensory CIDP including CISP, pure sensory DADS or pure sensory LSS. 
We adhered to the criteria of the EFNS/PNS[1] for the diagnosis of typical CIDP but we also 
included under this diagnosis patients with bilateral, although asymmetric, but not multifocal, motor 
and sensory impairment (at least one MRC point difference between the two sides). 
Table 1 Proposed clinical diagnostic criteria for atypical CIDP  
   DADS  
Mandatory criteria  
A) with or B) without increased distal motor latency 
1. Symmetric, sensory or sensorimotor symptoms and signs starting distally in the lower limbs, without proximal limb – trunk - face 
involvement  (length-dependent fashion) ¥ 
Other possible symptoms 
1. Ataxia, neuropathic pain, cramps, fatigue, autonomic symptoms, tremor 
2. Upper-limb distal sensory or sensorimotor symptoms and signs occurring later (at least after one year from onset) 
Exclusion criteria 
1. Cranial nerve involvement 
2. Proximal limbs, trunk, face involvement 
3. Weakness without sensory symptoms 
4. Symptoms and signs starting in the upper limbs 
PURE SENSORY CIDP 
Mandatory criteria  
A) with or B) without abnormal motor nerve conduction studies 
1. Sensory symptoms (including ataxia), without weakness, in a polineuropathic distribution, symmetric or asymmetric ¥ 
2. Symptoms may start anywhere in the body excluding a length-dependent pattern (included under DADS) 
Other possible symptoms 
1. Neuropathic pain, fatigue, tremor 
2. Facial sensory symptoms  
Exclusion criteria 
1. Motor symptoms/signs including cramps and motor cranial nerve palsy 
2. Multifocal distribution 
3. Autonomic dysfunction 
 
 CISP  
Mandatory criteria 
1. Sensory symptoms with a polyneuropathic distribution without weakness ¥ 
2. Normal motor and sensory nerve conduction and EMG studies 
• PLUS at least two of the following: 
3. Abnormal SSEP not due to CNS involvement 
4. MRI showing gadolinium enhancement and/or hypertrophy of the cauda equina, lumbosacral or cervical nerve roots, or the brachial or 
lumbosacral plexuses  
5. Elevated CSF protein level with normal cells 
Exclusion criteria and other possible symptoms 
1. As in pure sensory CIDP 
 
 PURE MOTOR CIDP  
Mandatory criteria  
A) with or B) without abnormal sensory nerve conduction studies 
1. Weakness, without sensory symptoms or signs, in a polineuropathic distribution, symmetric or asymmetric. ¥ 
2. Symptoms may start anywhere in the body 
Other possible symptoms 
1. Cramps, fatigue, tremor  
2. Motor cranial nerve palsy 
Exclusion criteria 
1. Sensory symptoms/signs including sensory ataxia 
2. Autonomic dysfunction 
3. Neuropathic pain 
4. Multifocal distribution  
 
 LSS  
Mandatory criteria  
A) with or B) without motor conduction block 
1. Sensory symptoms, with or without weakness, in a multifocal distribution (unilateral focalΩ CIDP included) ¥ 
2. Symptoms may start anywhere in the body 
Other possible symptoms 
1. Cramps, fatigue, autonomic symptoms, ataxia, neuropathic pain 
2. Motor and/or sensory cranial nerve palsy 
Exclusion criteria 
1. Weakness in isolation, without sensory symptoms 
2. Symptoms/signs in a polyneuropathic distribution 
 
¥ Clinical phenotype must have lasted at least one year (temporal criterion).  
Ω Focal CIDP defined as the presence of symptoms homogeneously restricted to the nerves of one limb or two limbs 
(ipsilateral upper and lower limb). 
CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; CISP = chronic immune sensory 
polyradiculopathy; DADS = distal acquired demyelinating symmetric neuropathy; LSS = Lewis-Sumner syndrome; 
SSEP = somatosensory evoked potentials 
Some authors also included additional specific electrodiagnostic parameters for the diagnosis of 
atypical CIDP (supplementary table 1) even if these were not considered in the EFNS/PNS 
Guidelines for CIDP. These parameters include abnormally increased motor distal latency (DL) in 
patients with DADS, normal sensory nerve conduction studies in patients with purely motor CIDP, 
normal motor nerve conduction studies in sensory CIDP, and presence of conduction blocks (CBs) 
in LSS. In our study, we used the electrodiagnostic criteria of the EFNS/PNS for the diagnosis of 
CIDP and its variants [1] but we restricted the diagnosis of atypical CIDP to clinical criteria to 
allow a retrospective analysis of the diagnosis at onset and of its evolution during the course of the 
disease. We compared however the data of patients within each group who fulfilled or not the 
additional electrodiagnostic parameters for the diagnosis of atypical CIDP at the time of inclusion in 
the study. Since the data on distal distance were not available, we did not calculate the terminal 
latency index in patients with DADS.  
Clinical assessment and ancillary tests 
At enrollment, all patients underwent a detailed clinical history including time of clinical onset, 
presence - distribution and date of onset of motor and sensory symptoms, ataxia, pain, tremor, 
cramps, fatigue, autonomic dysfunction, and cranial nerve involvement. This information was  
integrated with the data reported in the medical records. Disease course was defined as progressive, 
relapsing or monophasic by the treating neurologist. Response to previously performed therapy 
were reported by the treating neurologist as ‘improved’, ‘stable’ or ‘worsened’. Since the number of 
patients with atypical CIDP treated with other therapies besides steroids and intravenous 
immunoglobulin (IVIg) was relatively small, we focused our analysis on these two therapies. The 
clinical evaluation at enrollment included assessment of muscle strength using the Medical 
Research Council (MRC) sumscore on 12 muscles (range 0-60). Neurological disability was 
evaluated at enrollment with the Inflammatory-Rash Overall Built Disability Scale (I-RODS)(range 
1-48), and the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale (range 0-
10), while Quality of life (QoL) was assessed with the EuroQol-5D-3L scale (five items, each with 
a score from 1 -best- to 3 -worst). Results of previously performed examinations including CSF 
analysis, nerve ultrasound or brachial/lumbosacral plexus MR examination and sural nerve biopsy, 
were reported when available. The results of nerve conduction studies performed during the course 
of the disease were included. Sensory nerve conduction studies were performed bilaterally in 
median, ulnar and sural nerves and included evaluation of sensory nerve action potential (SNAP) 
amplitude, distal latency (DL) and sensory conduction velocity (SCV). Motor nerve conduction 
studies were also performed bilaterally in median, ulnar, common peroneal and tibial nerves and 
included distal and proximal compound muscle action potential (cMAP) amplitude (onset to peak) 
and duration, motor conduction velocity (MCV), distal and proximal motor latency and in most 
patients F-wave latency. Abnormalities of motor and sensory nerve conduction studies consistent 
with demyelination were defined according to the EFNS/PNS criteria.[1]  Some patients also 
underwent somatosensory evoked potentials (SSEP). At the time of inclusion, patients with an 
alternative diagnosis for the neuropathy or high titers of anti-MAG (myelin-associated 
glycoprotein) antibodies (over 7000 [BTU] by Bühlman method) or without available nerve 
conduction studies were excluded. In all the patients, the diagnosis at entry was revised by the 
coordinating Center according to the above-mentioned diagnostic criteria (table 1). These criteria 
were also applied at clinical presentation based on symptoms present at onset and for at least one 
year. Progression of atypical to typical CIDP was based on the time of appearance of symptoms 
before the inclusion in the study. CIDP diagnosis was classified in ‘definite’, ‘probable’ or 
‘possible’ according to the EFNS\PNS criteria.[1]  
Statistical analysis 
Descriptive statistics were reported for the entire sample of patients with CIDP, and for typical and 
the atypical CIDP forms separately. Categorical variables were described using frequencies and 
percentages, while continuous variables using mean, medians, and ranges. Demographic, clinical 
and neurophysiological features, treatment response, strength deficit, disability level and quality of 
life were compared between different subgroups of patients with the chi-square or the Fisher’s exact 
test for categorical variables, and with the t-test or the Wilcoxon-Mann-Whitney test for continuous 
variables. For patients with atypical CIDP at onset, the progression rate from atypical to typical 
CIDP was calculated using Kaplan-Meier survival curves, considering the different atypical forms 
separately. All tests were two-tailed and the significance level was set to 0.05. Analyses were 
performed with SAS version 9.4 (SAS Institute, Cary, NC, USA).  
RESULTS 
Frequency and clinical course of atypical CIDP 
By April 2018, 500 patients were enrolled in the database. Twenty-three patients were excluded 
from the analysis for the presence of an alternative diagnosis (18 patients with anti-MAG titers 
ranging from 9,300 to over 70,000 BTU, median 41,191 BTU), one with Charcot-Marie Tooth 1A, 
three with amyloidosis, and one with only cranial nerve palsy), and 17 for the absence of available 
nerve conduction studies or incomplete data. A total 460 patients were included in the study (293 
men; 167 women), aged 11-92 years, (mean 58; median 60 years), with mean disease duration of 
8.3 years (range 0.5-60 years, median 6 years). 
At study entry, 376 (82%) patients had a diagnosis of typical CIDP and 84 (18%) of atypical CIDP. 
The diagnosis fulfilled the EFNS/PNS diagnostic criteria for CIDP in 82% of the patients with 
typical CIDP and in 76% of those with atypical CIDP (p= 0.2149). Among the patients with 
atypical CIDP, 34 (7% of total CIDP patients) had DADS, 17 (4%) had purely motor CIDP, 17 (4 
%) had LSS including three with focal CIDP, and 16 (3.5%) had purely sensory CIDP including 
two (0.5%) with CISP (figure 1B). When we retrospectively reviewed the symptoms and signs at 
disease onset, we found that 180 (39%) patients fulfilled the diagnosis of atypical CIDP. This 
included 59 (13%) patients with DADS, 49 (11%) with purely sensory CIDP including two with 
CISP, 40 (9%) with purely motor CIDP, 29 (6%) with LSS, and three (1%) with CIDP clinically 
restricted to cranial nerves (cranial CIDP) (figure 1A). Ninety-six (53%) patients with atypical 
CIDP at onset progressed to typical CIDP after mean disease duration of 5.5 years (range 1-38; 
median 3) including 25/59 (42%) with DADS, 33/49 (67%) with purely sensory CIDP, 23/40 
(57.5%) with purely motor CIDP, 12/29 (41%) with LSS, and 3 with cranial CIDP. Figure 2 shows 
the yearly progression rate to typical CIDP for patients with different atypical CIDP forms at onset. 
The clinical form with the highest progression rate was pure sensory CIDP, while DADS showed 
the lowest rate. Within 5 years, 48% of sensory CIDP patients, 32% of pure motor, 36% of LSS and 
24% of DADS had progressed to typical CIDP; the corresponding values at 10 years were 77%, 
64%, 63% and 39% (figure 2). Patients with atypical CIDP who progressed to typical CIDP had 
longer disease duration compared to patients who did not progress (mean, 11 vs 7 years; p=0.0016).  
Clinical and electrophysiological features of the different forms of atypical CIDP 
In table 2 are summarized the clinical features and treatment response of the patients with different 
forms of atypical CIDP in comparison to patients with typical CIDP. 
Table 2 Comparison of clinical features and treatment response in atypical and typical CIDP 
 DADS 
(n. 34) 
Pure sensory 
(n. 16) 
Pure motor 
(n. 17) 
LSS 
(n. 17) 
Typical CIDP 
(n. 376) P value 
Gender (M:F) 24:10 10:6 8:9 16:1 235:141 0.0079**** 
Age at onset; years; 
mean (range) 58 (20-79) 57 (31-75) 53 (11-82) 48 (27-75) 49 (5-86) 0.0032* 
Disease duration; 
years; mean (range) 8 (0.5-26) 5 (0.5-17) 10 (0.5-28) 7 (0.5-24) 8.5 (0.5-60) NS 
Fulfillment of 
EFNS/PNS criteria 24 (70.5%) 12 (75%) 15 (88%) 13 (76%) 310 (82%) NS 
 
Increased CSF 
proteins;  
positive/tested 
 
 
Mean CSF proteins; 
mg/dL (range) 
 
26/29 (90%) 
 
 
 
93 (52-379) 
10/15 (67%) 
 
 
 
86 (46-193) 
7/9 (78%) 
 
 
 
171 (47-679) 
5/13 (38%) 
 
 
 
82 (61-146) 
243/284 (85.5%) 
 
 
 
123 (46-1000) 
0.0002**** 
 
 
 
NS 
Nerve imaging; 
positive/tested 7/7 5/5 0/0 6/7 (86%) 26/36 (72%) NS 
Nerve biopsy; 
positive/tested 2/4 (50%) 1/4 (25%) 0/0 0/1 21/36 (58%) NS 
MRC sum score; 
mean (range) 58 (48-60) 60 (60-60) 51 (36-60) 57 (49-60) 53.5 (26-60) 0.0003* 
I-RODS score; 
mean (range) 39 (16-48) 38 (23-47) 31 (11-48) 40 (26-47) 33 (1-48) 
0.0027*; 
0.0301**** 
INCAT disability 
score; mean (range) 1.5 (0-6) 1.7 (0-3) 3.5 (0-10) 2 (0-6) 2.7 (0-10) 0.0005* 
Quality of life score; 
mean (range) 7 (1-9) 7 (5-9) 8 (5-13) 7 (5-9) 8 (5-14) 0.0030* 
Overall treatment 
response 16/25 (64%) 9/10 (90%) 15/17 (88%) 9/14 (64%) 299/344 (87%) 
0.0050*; 
0.0326**** 
EFNS/PNS only 9/15 (60%) 8/8 (100%) 14/15 (93%) 7/11 (63%) 191/216 (88%) 0.0107* 0.0075**** 
Corticosteroids 9/16 (56%) 4/6 (67%) 3/7 (43%) 3/7 (43%) 110/215 (51%) NS 
Intravenous 
immunoglobulin 9/18 (50%) 6/7 (86%) 14/17 (82%) 5/12 (42%) 233/299 (78%) 
0.0178*; 
0.0086**** 
EFNS/PNS only 6/12(50%) 4/5 (80%) 13/16 (82%) 2/7 (29%) 139/185 (75%) 0.0852* 0.0151**** 
* Typical CIDP vs DADS, **Typical CIDP vs Pure sensory, *** Typical CIDP vs Pure motor, **** Typical CIDP vs 
LSS. 
CIDP = chronic inflammatory demyelinating polyradiculoneuropathy ; DADS = distal acquired demyelinating 
symmetric neuropathy; F = female; INCAT = Inflammatory Neuropathy Cause and Treatment ;  I-RODS = 
Inflammatory Rasch Overall Disability Scale ; LSS = Lewis-Sumner syndrome ; M = male ; MRC = Medical Research 
Council ; NS = not significant  
DADS. Thirty-four patients had a diagnosis of DADS at study entry including 22 with only sensory 
symptoms without weakness. All patients had a symmetric presentation of symptoms and signs 
distally in the lower limbs. Compared to typical CIDP, patients with DADS had an older age at 
onset (mean 58 vs 49 years; p= 0.0032). At onset, 26 (76%) patients presented with purely sensory 
symptoms while eight (24%) also had ankle weakness at presentation. After a mean disease 
duration of 8 years (range 0.5-26 years), sensory symptoms had progressed to involve also distal 
upper limbs in 12 (35%) patients, while 12 (35%) patients had distal weakness that in eight was 
restricted to the lower limbs. Ataxia was present in 16 (47%) patients, five (15%) had postural and 
intention tremor in the arms, and 14 (41%) patients had pain. Disease course was chronic-
progressive in 18 (53%) patients, relapsing in 14 (41%) patients and monophasic in two patients.  
Twenty-four (70.5%) patients met the EFNS/PNS diagnostic criteria for CIDP (21 definite, three 
probable). Seven of them had increased motor DL. Even if there were some differences between 
patients with (7 patients) or without (17 patients) increased motor DL in terms of frequency of 
upper-limb involvement (28.5% vs 47% patients; p= 0.6921) and presence of weakness (14% vs 
41% patients; p= 0.6417), none of the differences was significant.  
Compared with typical CIDP, DADS patients had higher MRC sumscore (mean 58 vs 53.5; p= 
0.0003), lower disability levels measured with INCAT (mean 1.5 vs 2.7; p= 0.0005) and I-RODS 
(mean 39 vs 33; p= 0.0027), and better QoL (mean 7 vs 8; p= 0.0030). 
PURELY SENSORY CIDP. Sixteen patients had a diagnosis of purely sensory CIDP at study entry 
including two with CISP. In three patients sensory symptoms were confined to the upper limbs, in 
three patients to the proximal and distal areas of the lower limbs, in nine patients to the four limbs, 
and in one patient to the face - trunk and the four limbs. Strength was normal in all patients. Ataxia 
and fatigue were reported by three (19%) and four (25%) patients, respectively. The clinical course 
was relapsing in seven (44%) patients, progressive in eight (50%) patients and monophasic in one. 
Twelve (75%) patients met the EFNS/PNS diagnostic criteria for CIDP (11 definite, one probable) 
with demyelinating features on motor conduction studies despite the absence of motor symptoms 
and signs.  
No significant difference between purely sensory and typical CIDP was found in terms of severity 
assessed with INCAT (mean, 1.7 vs 2.7; p= 0.0532) and I-RODS (mean, 38 vs 33; p= 0.0799), and 
QoL (mean, 7 vs 8; p= 0.1310). 
PURELY MOTOR CIDP. Seventeen patients had a diagnosis of purely motor CIDP at study entry. 
All patients presented with weakness without sensory symptoms, initially distributed in the upper 
limbs in two (12%) patients, in the lower limbs in nine (53%) patients and in the four limbs in six 
(35%) patients. After mean disease duration of 10 years (0.5-28 years), 12 (70.5%) patients had 
weakness in the proximal and distal muscles of the four limbs while clinical involvement remained 
confined to the upper limbs in one (6%) patient and to the lower limbs in four (23.5%) patients. In 
four (23.5%) patients, clinical manifestations were asymmetric without a multifocal distribution. 
Sensory examination was normal in all patients. Disease course was relapsing in seven (41%) 
patients and chronic progressive in 10 (59%) patients. 
Fifteen (88%) patients met the EFNS/PNS criteria of CIDP (14 definite, one possible). The most 
common electrophysiological findings in these patients were CBs (11 patients) and reduced MCV 
(nine patients). Sensory nerve conduction studies were normal in only five patients despite the 
absence of sensory symptoms. There was no significant clinical difference between patients with or 
without abnormal sensory conduction studies.  
No significant difference between purely motor and typical CIDP was found in terms of severity of 
motor impairment measured with MRC sumscore (mean, 51 vs 53.5; p= 0.1792), disability by the 
INCAT (mean, 3.5 vs 2.7; p= 0.0972) and I-RODS (mean, 31 vs 33; p= 0.7017), and QoL (mean 8 
vs 8; p= 0.9260).  
LSS. Seventeen patients had a diagnosis of LSS at study entry. Compared with typical CIDP, LSS 
patients more frequently were males (p= 0.0079). Initial symptoms were exclusively sensory in 
three (18%) patients and sensorimotor in 14 (82%), with symptoms and signs predominantly 
confined to one upper limb in four (23.5%), one lower limb in six (35%), and one upper plus one 
lower limb in four (24%) patients. Three (18)% patients had focal CIDP, with symptoms in only 
one limb. All but two patients developed sensorimotor disturbances after a mean of 7 years (range 
0.5-24 years). The clinical course was relapsing in eight (47%) patients, progressive in six (35%) 
patients and monophasic in three (18%) patients. 
Thirteen patients (76%) met the EFNS/PNS criteria for CIDP (11 definite, one probable, one 
possible) including eleven with CBs in motor nerves. There was no difference between patients 
with or without CBs in terms of presence of weakness (90% vs 83%; p= 1.0000) and frequency of 
involvement of upper and lower limbs (44% vs 57%; p= 0.6284). 
Patients with LSS had less disability by I-RODS (mean, 40 vs 33; p= 0.0301) but not INCAT 
(mean, 2 vs 2.7; p= 0.2063) compared to patients with typical CIDP, with similar MRC values 
(mean, 57 vs 53.5; p= 0.0778) and QoL (mean 7 vs 8; p= 0.2453).  
Response to therapy in atypical CIDP 
In table 2 is summarized the response to treatment in patients with atypical CIDP. Response to one 
or more therapy was reported in 16/25 (64%) treated patients with DADS including 9/15 (60%) 
fulfilling the EFNS\PNS criteria. There was no difference in treatment response between DADS 
patients with sensory or sensorimotor disturbance and between DADS patients with or without 
increased motor DL. Response to therapy occurred in 9/10 (90%) treated patients with sensory 
CIDP including 8/8 (100%) fulfilling the EFNS/PNS criteria. Improvement was also observed in 
15/17 (88%) treated patients with purely motor CIDP, including 14/15 (93%) patients fulfilling the 
EFNS/PNS criteria. There was no difference in the overall response to therapy between patients 
with purely motor CIDP with or without abnormal sensory nerve conduction studies. Response to 
steroids was also observed in 3/7 (43%) patients with purely motor CIDP patients. None of the 
patients with normal sensory nerve conduction studies improved however after steroid therapy 
while all improved patients had abnormal sensory conduction studies. Response to therapy was 
reported in 9/14 (64%) treated patients with LSS, including 7/11 (63%) patients fulfilling the 
EFNS/PNS criteria. There was no difference between LSS patients with or without CBs. 
Compared with typical CIDP, the overall response to treatment was significantly lower in patients 
with DADS (p= 0.0050) and LSS (p= 0.0326) even when we restricted the analysis to patients 
fulfilling EFNS/PNS criteria that in all but one patient with LSS and two with typical CIDP were 
consistent with definite or probable CIDP (table 2). The same occurred for patients with purely 
sensory DADS (p= 0.0109) but not for patients with purely sensory (p= 1.000) or purely motor 
CIDP (p= 0.7182). Patients with DADS and LSS also had a less frequent response to IVIg (p= 
0.0178 and p= 0.0086) compared to typical CIDP and the same occurred for patients fulfilling 
EFNS/PNS criteria even if the difference remained significant only for LSS (table 2). A less 
frequent response to IVIg was also observed in patients with sensory DADS (p= 0.0108) but not in 
patients with pure motor o pure sensory CIDP. There was no difference among the different groups 
in the response to steroids. Among the patients with typical CIDP, 235 (62.5%) patients had 
symmetric CIDP while 141 (37.5%) an asymmetric but not multifocal CIDP (> 1 MRC point 
difference between the two sides), and 36 (9.5%) patients had slightly asymmetric (but not 
multifocal) CIDP (1 MRC point difference between the two sides). There was no difference 
between patients with symmetric or asymmetric CIDP in the overall response to therapy (87% vs 
87%; p= 1.0000) or in the response to IVIg (78% vs 78%; p= 1.0000) or steroids (48% vs 56%; p= 
0.3533) while the difference in the overall response to treatment (p= 0.0384) and to IVIg (p= 0.01) 
remained significant between patients with either symmetric or asymmetric typical CIDP and LSS. 
(Verifica i dati) 
  
DISCUSSION 
There is some discrepancy on the frequency of the CIDP variants with numbers ranging from 1 to 
49%.[2,3] It is unclear whether this discrepancy reflects the use of different diagnostic criteria in 
previous studies or a different disease duration at the time of ascertainment. There are indeed some 
differences in the definition of these phenotypes.[4-29] We applied our set of diagnostic criteria to 
all our patients and found that the frequency of atypical CIDP at study entry was 18%, similarly to 
some previous studies (17.8-19.6%).[10,11] When we retrospectively analyzed the symptoms at the 
time disease onset and for the following year, we found that 39% of the patients had a clinical 
presentation consistent with atypical CIDP that in 53% of the patients evolved to typical CIDP by 
the time of inclusion in the study. A similar rate of progression (20-71%) was previously reported in 
other small series of patients.[5,8,12] In our study, progression to typical CIDP was significantly 
associated with a longer disease duration. Still, 55% of our patients with atypical CIDP at study 
entry had a disease duration of at least 5 years and 30% of at least 10 years. This finding supports 
the idea that progression to typical CIDP is often, though not invariably, associated with the disease 
duration. Some patients with typical CIDP presented some clinical modifications during the course 
of the disease leading to a predominantly distal or sensory but not motor or multifocal impairment, 
even if the previously more diffuse and sensorimotor impairment did not lead to a change in their 
diagnosis. There are also some differences in the reported frequency of the different forms of 
atypical CIDP. The relatively small prevalence of LSS in our series (4%) compared to some 
previous series (0.5-34%)[3,6,10,11,13] may reflect the inclusion in our series of only patients with 
a multifocal neuropathy and not of those with an asymmetric polyneuropathy. This decision was 
also supported by the absence of difference in the response to therapy between patients with 
symmetric or asymmetric typical CIDP, and by the finding that almost 40% of the patients with 
typical CIDP in our cohort had some degree of asymmetry, a figure that is more indicative of a 
typical form rather than an atypical form. Similarly, we found a lower prevalence of sensory CIDP 
(3.5%) compared to previous series (11-35%).[14,15] This may partly reflect our use of stringent 
diagnostic criteria with the proportion of patients raising to 7.8% if we also included patients with 
purely sensory DADS or LSS. It is also possible that the disease duration explains the difference 
with a prevalence of sensory CIDP in our series decreasing from 11% at onset to 3.5% at 
enrollment. DADS was the most common CIDP variant in our study (7%), (2-17% in previous 
studies),[2,6,10] followed by the purely motor form (4%) (4-10% in previous series).[2,10,13] 
Only few studies have compared disability in typical and atypical CIDP.[6,30,31] Two studies 
found a higher level of disability and impairment in typical CIDP than in LSS and DADS 
patients.[6,30] Another study did not find difference in terms of disability between typical and 
atypical CIDP.[31] In our series, patients with typical CIDP had a worse MRC score, higher 
disability and worse QoL than patients with DADS, confirming that DADS is clinically less 
disabling than typical CIDP. Patients with LSS had less severe disability than patients with typical 
CIDP by I-RODS but not by INCAT. This discrepancy may reflect the wider range of item 
difficulties in the I-RODS than INCAT scale. On the other hand we did not find differences in the 
degree of motor impairment, disability and QoL between purely motor CIDP patients and typical 
CIDP patients. Similarly, disability and QoL where similar in sensory and typical CIDP.  
There are some differences in the reported response to therapy in patients with atypical CIDP. A 
better response to IVIg than to steroids was reported in some series of patients with 
LSS,[4,5,7,16,17] while others[6] reported a reduced response to IVIg but not to steroids compared 
to typical CIDP. Patients with DADS were reported to have a less satisfactory response to treatment 
than patients with typical CIDP.[18,19] In our series, patients with LSS and DADS had a less 
frequent response to therapy (p= 0.0326; p= 0.0050) and to IVIg (p= 0.0086; p= 0.0178) compared 
to patients with typical CIDP and the same occurred for patients with purely sensory DADS, while 
there was no differences in the response to steroids. 
Several reports suggest that purely motor CIDP may not respond to or even worsen after 
corticosteroids.[20,21] Based on these findings, the EFNS/PNS Guidelines recommend the use of 
IVIg for motor  CIDP.[1] However, response to steroids has been reported in other studies, with 
figures up to 20% of treated patients.[13] We found that 43% of our purely motor CIDP patients 
improved after steroids. All these patients had however a concomitant sensory electrophysiological, 
although not clinical, impairment. This finding suggest that the diagnosis of motor CIDP and the 
decision to avoid steroids should be probably restricted to patients without any clinical and 
electrophysiological involvement of motor nerves. Only few data are available on the response to 
therapies in patients with purely sensory CIDP with a usually favourable response to both IVIg and 
steroids.[13,22-24] We also found a similar response rate in comparison to patients with typical 
CIDP.  
In conclusion, our study on a large population of patients classified according to a uniform set of 
diagnostic criteria, confirms that the proportion of patients with atypical CIDP varies according to 
the duration of the disease and that response to therapy is different in some of these forms (DADS 
and LSS). The persistence of an atypical presentation in a consistent proportion of patients for 
several years together with the different response to therapy in some of these forms, suggest that 
some difference in the pathogenic mechanisms may underlie some of these variants. An extensive 
immunological study to investigate the presence of different anti-nerve antibodies is in progress in 
this cohort of patients to verify whether the different clinical presentations and response to therapy 
might be associated with specific immunological abnormalities as was recently reported for patients 
with antibodies to neurofascin 155, contactin 1 and other nodal-paranodal proteins.[32,33] It would 
be also advisable to verify these data in a prospective study on a large series of newly diagnosed 
patients in whom a definite set of diagnostic criteria and of diagnostic investigations and assessment 
would be applied and subsequently periodically verified.[34] 
 
 
Figure 1A. CIDP type at one year after onset of symptoms; B CIDP type at study entry (mean 8 years after 
onset).  
Graphs show the frequency of the atypical CIDP variants at one year after the onset of symptoms (A) and at study entry 
(B) in 460 patients.  
Figure 2 Probability of progressing from atypical CIDP to typical CIDP.  
Graph shows the yearly progression rate to typical CIDP of the individual atypical CIDP forms at onset.  
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